Percutaneous closure of symptomatic ventricular septal defects in children can be achieved with off-label use of an occluder device. A research letter published online November 7, 2012, ahead of print ...
In children with perimembranous ventricular septal defects (VSDs), closure with a catheter-delivered occluder device is safe, providing midterm outcomes similar to those of open-heart surgery, ...
After bicuspid aortic valve, ventricular septal defects (VSDs) are the most common congenital heart abnormalities. Of all congenital defects, around 20% are solitary lesions and another 10% are ...
New transcatheter device for closing postinfarction ventricular septal defects may be safer than sur
Chicago, IL - A nonrandomized trial of a new ventricular septal occluder designed specifically for the closure of defects that occur post-MI suggests that while mortality is still high following the ...
A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...
Atheart Medical Inc. came on the market with splash, simultaneously announcing the company’s formation and its launch of a U.S. investigational device exemption (IDE) trial for the Resept ASD occluder ...
LONDON--(BUSINESS WIRE)--The global heart defect closure devices market research report by Technavio predicts the market to post a CAGR of more than 29% during the period 2019-2023. A key driver for ...
The growth in the heart closure devices market from 2024-2030 is mainly driven by several factors: the rising incidence of congenital heart defects, increased use of MRI procedures, greater awareness ...
BOSTON--(BUSINESS WIRE)-- NMT Medical, Inc. (NASDAQ: NMTI), an advanced medical technology company that designs, develops, manufactures and markets proprietary implant technologies that allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results